Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage, has been reported after 2 years of UDCA therapy. Thus, longer follow–up may be necessary to determine whether UDCA has a favorable effect on histological stage of disease and progression to cirrhosis. Our aim was to determine the long–term effects of UDCA therapy on histological stage and progression to cirrhosis in patients with PBC. Sixteen unselected patients with noncirrhotic PBC who had been on long–term UDCA therapy (13–15 mg/kg/d) for 6.6 ± 0.4 years (range, 5–9 years) were identified and their histological finding during treatment compared with that of 51 noncirrhotic patients with PBC who had received ineffective therapy (d–penicillamine [DPCA] or placebo) for 5.6 ± 0.07 years (range, 5–8 years). Histological stage was determined using the Ludwig classification. The rate of progression to cirrhosis (stage 4) was significantly less in the UDCA group than in the control group (13% vs. 49%P= .009). Although the overall rate of progression of histological stage was less in the UDCA group than in the control group (50% vs. 71%), this difference was not significant (P= .1). A marked improvement in liver biochemistries and Mayo risk score was noted in all patients during UDCA therapy; however, this improvement was not significantly different between patients who progressed and those who did not. In conclusion, long–term UDCA therapy appeared to delay the development of cirrhosis in PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationKaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Self-citation
Research works printed but not linked: 7
- Combes, 1995, Hepatology, 22, 759
- Emmond, 1996, Hepatology, 24, 168a
- Dickson, 1989, 10 Hepatology, 97, 1
- Kilmurry, 1996, Hepatology, 23, 1148
- Batts, 1996, Am J Gastroenterol, 91, 2314
- Lindor, 1995, Hepatology, 22, 1158
- Kaplan, 1987, Adv Inten Med, 32, 359
Cited by
Items 201–235 of 235
Orphan drugs in development for primary biliary cirrhosis: challenges and progress
Lindor, K. D., Ali, A. H., & Byrne, T. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s69477
Self-citationChapter 12 Primary Biliary Cirrhosis
Abdalian, R., & Heathcote, J. (2008) · Technical report · doi:10.1016/s1571-5078(07)00012-8
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
The Pointy End of the NAFLD Iceberg: Cirrhosis, Portal Hypertension, and Liver Failure
Schwake, J. W., Torres, D. M., & Harrison, S. A. (2013) · doi:10.1002/9781118556153.ch16
Poupon, R. Y. (2011) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(11)70560-5
Prognosis of Korean patients with primary biliary cirrhosis
Song, B. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.2.109
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
“Other lines of evidence indicate that histological stage progression was delayed by UDCA compared with historical data [82].”
ResultPrimär-biliäre Zirrhose, primärsklerosierende Cholangitis und „Vanishing-bile-duct“-Syndrom
Leuschner, U. (2001) · Springer eBooks · doi:10.1007/978-3-642-56819-0_5
Aus der Medizinischen Universitätsklinik und Poliklinik Tübingen
Medizin, A. I., & Kanz, L. (2007)
Çetin, H., Akdeniz, S. K., Olgar, Ş., Öktem, F., Dündar, B. N., & Ayata, A. (2009) · DergiPark (Istanbul University) · doi:10.17343/sdutfd.81291
Targets and investigative treatments for primary biliary cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1227240
Self-citationAutoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
Self-citationChallenges and opportunities in the management of portal hypertension
Patanwala, I. (2015)
Therapy of primary biliary cirrhosis
Poupon, R. Y., Corpechot, C., & Poupon, R. E. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_28
Abdalian, R., Heathcote, J., & Ramos‐Casals, M. (2017) · Technical report · doi:10.1016/b978-0-444-63707-9.00005-2
Transition from Conventional Drugs to Promising Drugs for Primary Biliary Cholangitis
Dohmen, K. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.04.555634
Racial disparity in primary biliary cholangitis (pbc) patients seen in an urban academic gi clinic
Naylor, P. H., Tama, M., Goyal, S., Kathi, P. R., Ehrinpreis, M. N., & Mutchnick, M. G. (2018) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2018.09.00301
Júnior, A., Menezes, L. V. P., Fahham, L., Fernandes, R. Z. S., & Teich, V. (2018) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v10.n1.p45-55
Treatment of Recurrent Nonviral Disease
Neuberger, J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00051-6
Diseases of the Liver: Primary Biliary Cholangitis
Phillips, P. K., & Said, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-25626-5_7
Faculty Opinions recommendation of Ursodeoxycholic acid for primary biliary cirrhosis.
Rosenthal, P. J. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717969424.793469137
Dancygier, H. (2003) · Springer eBooks · doi:10.1007/978-3-642-55902-0_25
Cholangitis and cholangiodysplasia
(2006) · Springer eBooks · doi:10.1007/3-540-28977-1_32
Kuntz, E., & Kuntz, H.-D. (2002) · Springer eBooks · doi:10.1007/978-3-662-04680-7_32
Trauner, M., & Boyer, J. L. (2000) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200005000-00006
Scheinberg, A. R., & Levy, C. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00384-z
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Ursodeoxycholic acid in hepatobiliary diseases
Kim, H., & Yoo, J. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.9.603
Gotaro, T. O. D. A., 大海, 石., 三朗, 大., Okanoue, T., 森一, 恩., Kako, M., Kaneko, S., Kamimura, T., 寛中, 川., Sata, M., et al. (2011) · Kanzo · doi:10.2957/kanzo.52.584 · Cited by 1
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
Yamashita, Y., Kimura, T., Fujita, K., Okumura, T., Iwadare, T., Kobayashi, H., Wakabayashi, S., Yamazaki, T., Joshita, S., Umemura, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70223 · Cited by 1
van der Meer, A. J., & Trivedi, P. J. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch20
Metadata
- Authors
- Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 644-647
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1993958712
- Cited by
- 234
- References
- 24
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 10 · 2021: 2 · 2020: 5 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6028 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, histological progression, long-term treatment, Ludwig classification, D-penicillamine, Mayo risk score, cholestatic liver disease, liver histopathology
- MeSH terms
- Adult, Aged, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Penicillamine, Time Factors, Ursodeoxycholic Acid, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.